Dr. Douglas Throckmorton will testify before the House of Representatives Oversight and Government Reform Committee Hearing Reviewing the Rising Price of EpiPens on September 21st. Dr. Throckmorton is board certified in internal medicine and nephrology. As Deputy Director at the FDA Center for Drug Evaluation and Research, he shares the responsibility for overseeing the regulation of research, development, manufacture and marketing of prescription, over-the-counter, and generic drugs in the United States.
The congressional committee will be hearing from Heather Bresch, CEO of the global pharmaceutical company Mylan, Inc. Mylan has raised the price of their EpiPen product nearly 500% over the past few years. In Investigation of Skyrocketing Prescription Drug Prices, House panel co-chairmen, Republican Representative Jason Chaffetz and Democratic Representative Elijah Cummings state:
There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens. We look forward to receiving answers next week from Mylan about its dramatic price hike for this life-saving medication. We also plan to examine ways to encourage greater competition in the EpiPen market and to speed FDA’s approval of acceptable new generic applications. Our goal is to work together to ensure that critical medications, like the EpiPen, are accessible and affordable for all of our constituents.
Pharmacologists are qualified practitioners who specialize in medicine and the effects of drugs used in the treatment process. These professionals diagnose patients and match the right drug therapy to that diagnosis. They also study the use and effects of drugs after medications have been administered for the treatment of disease.